The Pulse
AstraZeneca and Oracle Target Clinical Trials With AI
AstraZeneca and Oracle announced a global AI collaboration focused on clinical-trial recruitment, earlier diagnosis and drug-safety monitoring. Their first planned programme will address hypertension care and clinical research in Abu Dhabi
AI.info Team · Written with AI · fact-checked ·
AstraZeneca and Oracle want to connect clinical research more directly to patient care, while promising that AstraZeneca will not receive identifiable patient information. The companies announced the collaboration on October 20, 2026, saying they will explore AI and real-world health data for trial recruitment, earlier diagnosis and safety monitoring. Their agreement is non-binding, and each proposed project must clear separate legal, privacy, regulatory, ethical and institutional reviews before it proceeds.
Abu Dhabi is the first test
The first programme will focus on hypertension care and clinical research in Abu Dhabi, in partnership with healthcare company M42. The work is intended to help clinical teams identify patients with uncontrolled hypertension, support care guided by clinical guidelines and improve recruitment into trials. AstraZeneca and Oracle have not announced a timetable, trial enrolment target or performance measure for the programme.
The Abu Dhabi project is the opening effort in a collaboration planned to span projects in the United States, the Middle East and Europe, with local governments and applicable rules shaping how they proceed. AstraZeneca says the broader work will cover oncology; cardiovascular, renal and metabolic diseases; respiratory and immunology; and rare disease. The companies frame the projects as ways to test connections between research and clinical workflows, not as proof that AI has already improved recruitment or patient outcomes.
Data access comes with limits
The collaboration will use de-identified real-world data under governance, privacy and security arrangements, according to AstraZeneca’s announcement. AstraZeneca says it will not receive patient-identifiable information. The release does not specify which data sets the companies will use, how their AI systems will operate or what safeguards will apply beyond the stated review process.
That distinction matters to the proposed model: health systems would use data to identify people who may need care or could qualify for a study, while the drugmaker says it will not receive identifying details. The companies have not described the technical architecture or specified which party will control the data in each project. Each proposal still requires its own approvals before work begins.
A term sheet, not a funded rollout
The companies have signed a non-binding term-sheet agreement and disclosed no financial terms. That leaves the collaboration at an exploratory stage: the release describes areas of interest and the initial Abu Dhabi programme, but does not provide a binding project schedule or confirm wider deployment. Its stated next step is to assess individual projects against local rules and safeguards.
“Some of the most important opportunities for AI are in healthcare, where better use of data can help turn scientific innovation into better outcomes for patients.”
Mike Sicilia, chief executive officer, Oracle
Oracle says it will bring data, cloud, AI and clinical workflow capabilities; AstraZeneca contributes scientific, clinical-development and regulatory expertise. The companies’ first concrete focus is uncontrolled hypertension in Abu Dhabi, where clinical teams are meant to connect guideline-directed care with trial recruitment. Whether that approach can expand beyond the initial programme depends on the project reviews and on what the teams can demonstrate without sharing identifiable patient information with AstraZeneca.